Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 10/20 | 0.73 |
| ▸ | NOS3 | P29474 | 6/20 | 0.73 |
| ▸ | NOS1 | P29475 | 6/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12250784 | 0.91 | NOS2 (0.63) | NOS2NOS3NOS1ESR1IKBKB | |
| SCHEMBL27884616 | 0.89 | NOS2 (0.61) | NOS2NOS3NOS1ESR1IKBKB | |
| SCHEMBL12250770 | 0.89 | NOS2 (0.61) | NOS2NOS3NOS1ESR1IKBKB | |
| SCHEMBL12250722 | 0.89 | NOS2 (0.66) | NOS2NOS3NOS1ESR1IKBKB | |
| SCHEMBL23193450 | 0.88 | NOS2 (0.59) | NOS2NOS3NOS1ESR1 | |
| SCHEMBL7052362 | 0.85 | NOS2 (1.00) | NOS2NOS3NOS1 | |
| SCHEMBL12250783 | 0.82 | NOS2 (0.58) | NOS2NOS3NOS1ESR1 | |
| SCHEMBL12810594 | 0.80 | NOS2 (0.56) | NOS2NOS3NOS1ESR1IKBKB | |
| SCHEMBL17069066 | 0.80 | NOS2 (0.56) | NOS2NOS3NOS1ESR1IKBKB | |
| SCHEMBL1119955 | 0.80 | NOS2 (0.50) | NOS2NOS3NOS1ESR1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3316889-A1 | CORTISTATIN ANALOGUES AND SYNTHESES AND USES THEREOF | President and Fellows of Harvard College (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3294298-A1 | CORTISTATIN ANALOGUES, SYNTHESES, AND USES THEREOF | President and Fellows of Harvard College (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-3294418-A1 | TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH CORTISTATIN DERIVATIVES | President and Fellows of Harvard College (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20170224835-A1 | Antibody Drug Conjugates | SORRENTO THERAPEUTICS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170190736-A1 | Antibody Drug Conjugates | SORRENTO THERAPEUTICS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2017004411-A1 | CORTISTATIN ANALOGUES AND SYNTHESES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2016182904-A1 | TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH CORTISTATIN DERIVATIVES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016182932-A1 | CORTISTATIN ANALOGUES, SYNTHESES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-17 | — | — | WO | disclosed |
| EP-3087080-A1 | CORTISTATIN ANALOGUES AND SYNTHESES AND USES THEREOF | President and Fellows of Harvard College (US) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015100420-A1 | CORTISTATIN ANALOGUES AND SYNTHESES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-02 | — | — | WO | disclosed |
| WO-2012092512-A2 | CATALYTIC ANTI-MARKOVNIKOV OXIDATION AND HYDRATION OF OLEFINS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-07-05 | — | — | WO | disclosed |
| WO-2010129864-A9 | METHODS AND COMPOSITIONS FOR STUDYING, IMAGING, AND TREATING PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2195311-B1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009024905-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190736-A1 | Antibody Drug Conjugates | STT3B, STT3A, HSD17B14 | NOS2 4440/4885NOS3 3718/4885NOS1 4610/4885 |
| US-20170224835-A1 | Antibody Drug Conjugates | DARS1, CD38, AADAC | NOS2 3985/4885NOS3 3864/4885NOS1 4255/4885 |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | NOS2 2411/4885NOS3 2145/4885NOS1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.